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Malignant pleural mesothelioma (MPM) is an extremely aggressive plural 
malignancy mainly caused by asbestos exposure. Basic research about the immune 
suppressive tumor microenvironment in MPM has suggested that MPM might be 
a good candidate for immune therapy. Immunocheckpoint inhibitors have shown 
some promising results. A phase Ib trial with pembrolizumab, an antibody specific 
for the programmed cell death 1 protein (anti-PD-1), showed efficacy in patients 
with programmed death-ligand 1 (PD-L1)-positive MPM. Among 25 patients 
tested, 5 patients (20%) achieved a partial response. A Japanese group evalu-
ated the efficacy and safety of nivolumab, an anti-PD-L1 antibody, for patients 
with advanced MPM in a phase II study. Ten (29%) patients showed an objective 
response. Based on those results, nivolumab was approved in Japan for unresect-
able recurrent MPM. A phase III randomized study was conducted to compare 
nivolumab plus ipilimumab to platinum doublet chemotherapy as a first-line 
therapy in unresectable MPM. The primary endpoint, overall survival (OS), was 
significantly improved in the nivolumab plus ipilimumab group. Cellular therapies 
and cancer vaccines are limited by many challenges; therefore, improvements to 
overcome these difficulties are urgently warranted. Further research is needed, 
including large-scale clinical trials, to clarify the utility and safety of immuno-
therapy in MPM.
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1. Introduction
Malignant pleural mesothelioma (MPM) is an extremely aggressive plural 
malignancy, which is mainly caused by asbestos exposure [1]. The benefit of surgi-
cal resection is controversial, because only a minority of patients with MPM meets 
the criteria for surgery, and it is unrealistic to assume that surgery will achieve a 
complete tumor resection without a micro residual tumor. Systemic chemotherapy 
with platinum plus pemetrexed is the recommended first-line systemic therapy for 
advanced MPM. However, the median overall survival (OS) is only approximately 
12 months [2]. For patients that fail first-line chemotherapy, a standard second-line 
chemotherapy has not been defined [3]. Hence, it is critically essential to develop a 
new treatment option.
Recently, immunocheckpoint inhibitors (ICIs) have achieved great success in 
treating several cancer types [4–7]. Basic research about the immune-suppressive 
tumor microenvironment in MPM has suggested that MPM might be a good 
candidate for immune therapy [8, 9]. CD8+ tumor-infiltrating lymphocytes were 
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reported to predict a favorable prognosis after a resection of MPM [10]. In fact, 
recently, ICIs have shown promising results for patients with MPM.
In this chapter, we summarize recent studies on immunotherapy for MPM.
2. Anti-cytotoxic T-lymphocyte antigen 4 antibody
Anti-cytotoxic T-lymphoctye antigen 4 (CTLA-4) antibody was the first 
reported ICI for treating MPM. To date, three clinical trials have tested anti CTLA 4 
antibody monotherapy for MPM.
In the first phase II trial (MESOT-TREM-2008), the anti-CTLA-4 monoclonal 
antibody, tremelimumab (15 mg/kg) was administered intravenously once every 
90 days to patients with MPM [11]. Twenty-nine patients with MPM that had 
failed a first-line platinum-based regimen were enrolled. Of these, no patients 
achieved a complete response, 2 patients achieved a partial response, and 7 others 
achieved durable disease control. The median progression-free survival (PFS) was 
6.2 months, and the median OS was 10.7 months. The second phase II trial (MESOT-
TREM-2012), enrolled 29 patients with MPM that were treated with 10 mg/kg 
tremelimumab, initially every 4 weeks for 6 doses, then every 12 weeks [12]. The 
disease control rate was slightly improved after this regimen modification; one 
patient achieved a partial response, and 11 patients achieved disease control.
Based on these two trials, a large scale, randomized trial (DETERMINE) was 
conducted [13] with 571 patients with MPM. Of these, 382 patients were assigned 
to tremelimumab and 189 patients were assigned to placebo. However, there 
was no significant difference in PFS or OS between these two groups. After the 
DETERMINE trial, anti-CTLA-4 antibodies were investigated only in combina-
tion with an anti-programmed cell death protein 1 (anti-PD-1) antibody or anti-
programmed death ligand 1 (PD-L1) antibody.
3. Anti-PD-L1 antibody
Mansfield et al. reported that PD-L1 was expressed in approximately 42 of 
106 MPM specimens, and that PD-L1 expression was significantly correlated 
with poor survival (OS: 5 months in a PD-L1-positive group vs. 14.5 months in a 
PD-L1-negative group) [14]. Cedrés et al. also reported that PD-L1 expression was a 
negative prognostic factor in patients with MPM [15]. These results supported the 
notion that PD-L1 might serve as a potential target for immunotherapy in MPM.
Avelumab is a human IgG1 monoclonal antibody that binds to PD-L1 [16]. 
Hassan et al. described a phase I trial (JAVELIN Solid Tumor) that enrolled 53 
patients with unresectable MPM. Those patients had failed first-line chemotherapy 
with platinum and pemetrexed. When they were treated with avelumab, the objec-
tive response rate was 9% (one complete response and four partial responses) [17]. 
Responses were durable (median, 15.2 months), and they were observed both in 
patients with PD-L1-positive tumors (objective response rate [ORR]: 19%) and in 
those with PD-L1-negative tumors (ORR: 7%). The median PFS was 4.1 months, 
and median OS was 10.7 months.
Another anti-PD-L1 antibody, durvalumab, was recently evaluated for effi-
cacy in 54 patients with MPM that were not treated previously. Durvalumab was 
combined with cisplatin and pemetrexed as a first-line chemotherapy (DREAM 
trial) [18]. The ORR was 48%, and, 31/54 (57%) patients were progression-free at 
6 months. Based on the phase II trial results, a phase III trial is currently planned.
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Pembrolizumab is an antibody against PD-1. Pembrolizumab was tested for 
efficacy in 25 patients with PD-L1-positive MPM in a non-randomized, phase Ib 
trial [19]. Five patients (20%) achieved a partial response, and 72% of patients 
achieved disease control. The median OS was 18 months.
A phase II trial of pembrolizumab monotherapy was conducted in 65 patients 
with MPM that had been treated previously [20]. Among those patients, 19% 
achieved a partial response to pembrolizumab. The median PFS and OS were 4.5 
and 11.5 months, respectively.
Based on these two trials, pembrolizumab was administered, off-label, to 93 
patients with MPM in Switzerland and Australia [21]. The ORR was 18%, and 
the median PFS and OS were 3.1 months and 7.2 months, respectively. Patients 
with high PD-L1 expression showed improved ORR (44%) and PFS (6.2 months). 
Recently, a retrospective study from Australia analyzed data from patients with 
MPM that received pembrolizumab as the first-, second-, or subsequent-line treat-
ment. They found an ORR of 18%, and a disease control rate of 56%. The median 
PFS was 4.8 months, and the median OS was 9.5 months [22].
4.2 Nivolumab
Nivolumab is a fully humanized monoclonal anti-PD-1 antibody. It was first 
tested in 34 patients with recurrent MPM in the Netherlands [23]. In that single-
center trial, patients with MPM received 3 mg/kg intravenous nivolumab every 
2 weeks. Among 34 patients, 8 patients (24%) achieved a partial response, and 
another 8 patients (24%) displayed stable disease at 12 weeks.
A Japanese group also evaluated the efficacy and safety of nivolumab in 34 
patients with advanced MPM. That study tested nivolumab as a salvage therapy in a 
single-arm phase II study (MERIT study) [24]. Patients received 240 mg nivolumab 
intravenously every 2 weeks. Ten (29%) patients showed an objective response. 
The median duration of the response was 11.1 months, and the disease control rate 
was 68%. The median PFS and OS were 6.1 and 17.3 months, respectively. Among 
patients with PD-L1-positive tumors (≥1% expression), the ORR was 40%. Based 
on those results, nivolumab was approved in Japan for unresectable recurrent MPM.
5. Combination therapy with ICIs
Based on the favorable results obtained with ICI monotherapy, recent investiga-
tions tested combination treatments, with an anti-PD-1 or anti-PD-L1 antibody 
combined with an anti-CTLA-4 antibody. This combination was expected to 
maximize T-cell activation.
NIBIT-MESO-1 was open-label, non-randomized, phase II trial, in which 40 
patients with MPM received at least one dose each of tremelimumab and dur-
valumab [25]. Eleven patients (28%) displayed an objective response. The median 
PFS was 5.7 months and the median OS was 16.6 months.
IFCT-1501 MAPS2 was a multicenter, open-label, randomized, phase II trial, 
in which 108 patients with MPM were randomly assigned to receive intravenous 
nivolumab or intravenous nivolumab plus ipilimumab. In the intention-to-treat 












Agent Year N ORR (%) mPFS (mo) mOS (mo) Study type Reference
Anti-CTLA4
Tremelimumab 2013 29 7 6.2 10.7 2 Calabro et al. [11]
Tremelimumab 2015 20 3 6.2 11.3 2 Calabro et al. [12]
Tremelimumab 2017 571 5 2.8 7.7 2b Maio et al. [13]
Anti-PD-L1
Avelumab 2019 53 9 4.1 10.7 1b Hassen et al. [17]
Anti-PD-1
Pembrolizumab 2017 25 20 5.4 18 1b Alley et al. [19]
Pembrolizumab 2018 65 19 4.5 11.5 2 Desai et al. [20]
Nivolumab 2018 34 24 2.6 11.8 2 Quispel-Janssen et al. [23]
Nivolumab 2018 34 29 6.1 17.3 2 Okada et al. [24]
Combination therapy
Tremelimumab/Durvalumab 2018 40 28 5.7 16.6 2 Calabro et al. [25]
Nivolumab/Ipilimumab 2019 62 28 5.6 15.9 2 Scherpereel et al. [26]
Nivolumab 63 19 4 11.9
Nivolumab/Ipilimumab 2019 34 29 6.2 NR 2 Disselhorst et al. [27]
Nivolumab/Ipilimumab 2020 303 40 6.8 18.1 3 Baas et al. [28]
ORR: objective response rate; mPFS: median progression free survival; mo: months; mOS: median overall survival; CTLA: cytotoxic T-lymphocyte antigen; PD-L1: programmed death ligand 1; PD-1: 
programmed cell death protein 1.
Table 1. 
Overview of clinical trials that tested immunocheckpoint inhibitors for malignant pleural mesothelioma.
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(40%) patients in the nivolumab group and 32/62 (52%) patients in the combina-
tion group [26]. The INITIATE study also evaluated the efficacy of nivolumab 
combined with ipilimumab in patients with MPM. In that study, among 34 
patients included in the efficacy assessment, ten (29%) patients achieved a partial 
response, and 23 patients (68%) achieved 12 weeks of disease control [27]. Based 
on these favorable results, a phase III randomized study was conducted to compare 
nivolumab plus ipilimumab to platinum doublet chemotherapy as a first-line 
therapy in unresectable MPM. In that study, 303 patients were randomized to 
nivolumab plus ipilimumab and 302 patients were randomized to platinum doublet 
chemotherapy. With a minimum follow-up of 22 months, the primary endpoint, 
OS, was significantly improved with nivolumab plus ipilimumab compared to 
chemotherapy (median, 18.1 vs. 14.1 months; hazard ratio, 0.74; 95% confidence 
interval, 0.61–0.89; P = 0.002) [28].
Overview of clinical trials of that tested ICIs for MPM was summarized in 
Table 1.
6. Vaccine
Cancer vaccines have been tested for various cancer types. These vaccines have 
included tumor lysate, attenuated bacteria, and single or multiple peptides. Wilms 
tumor 1 (WT-1) is one of the most well investigated cancer antigens. WT-1 was 
expressed in tumors in 97% of patients with MPM [29]. Galinpepimut-S, a multi-
valent vaccine against the WT 1 peptide, can activate both CD4+ and CD8+ T-cells 
[30]. The efficacy and safety of galinpepimut-S was investigated in a phase II trial. 
The pilot study demonstrated that the median PFS was 7.4 months in the placebo 
group and 10.1 months in the vaccine group. The median OS was 18.3 months in 
the placebo group and 22.8 months in the vaccine group. Based on th0se findings, a 
clinical trial is currently ongoing to investigate a combination treatment of galin-
pepimut-S plus nivolumab in patients with MPM (with WT-1-positive tumors). 
Combining cancer vaccines with ICIs might improve the clinical outcome and open 
a new avenue of therapeutic strategies for MPM.
7. Dendritic cell therapy
Vaccination strategies have been developed that involve dendritic cells (DCs), 
which are antigen-presenting cells for T-cell activation. The DCs are pulsed with 
tumor lysate to overcome the shortcomings of autologous DCs. These strategies 
have shown remarkable anti-tumor activity, with low toxicity, in several cancer 
types. In the area of MPM, 9 patients received three vaccinations of autologous 
mature DCs loaded with autologous tumor cell lysate [31]. Among these patients, 
3 showed a partial response in the first 8 weeks after the DC vaccination. 
However, two of those three patients had received chemotherapy before the DC 
vaccination, which might have influenced the anti-tumor effect. In the next step 
of treatment, they added cyclophosphamide to increase the anti-tumor activity by 
inhibiting regulatory T cells [32]. Ten patients with MPM received cyclophospha-
mide and a vaccination of autologous mature DCs loaded with autologous tumor 
cell lysate. Of those ten patients, seven lived longer than 24 months, and the mean 
OS was 37 months.
Obtaining autologous tumor cell lysate is time consuming, because patients have 
to undergo multiple tumor biopsies. In one study, allogeneic tumor lysate obtained 
from a tumor cell line was applied to autologous DCs [33]. Nine patients with MPM 
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were treated with DC vaccinations (autologous DCs pulsed with tumor lysate from 
five mesothelioma cell lines). Of these, two patients experienced a partial response 
and all nine patients established disease control. The median OS was longer than 
22.8 months. Based on those promising results, an ongoing phase II/III study is 
currently testing DCs loaded with allogeneic tumor cell lysate as a maintenance 
therapy after chemotherapy (DENIM trial) [34].
8. Chimeric antigen receptor T-cell therapy
Chimeric antigen receptor (CAR) T-cells can be used to target specific tumor 
antigens directly. CAR T-cell therapy has shown clinical efficacy for hemato-
logical malignancies, and it was approved by the United States Food and Drug 
Administration for B cell acute leukemia and diffuse large B-cell lymphoma. Several 
clinical trials are ongoing to test CAR T-cell therapy on both hematological malig-
nancies and solid tumors [35]. CAR T-cells that targeted WT-1, fibroblast activation 
protein (FAP), or mesothelin (MSLN) were tested in a clinical trial on MPM. Hass 
et al. reported the results of a clinical trial for testing CAR T-cells that targeted 
MSLN on 15 patients with MPM. The CAR T-cells were applied as a monotherapy 
or in combination with low-dose cyclophosphamide, for solid tumors [36]. The 
best overall response was stable disease (11 of 15 patients). Currently, several phase 
I trials are ongoing to examine the efficacy of CAR T-cell therapy in solid tumors, 
including MPM.
9. Conclusion
The prognosis of MPM remains poor. A PD-1/PD-L1 blockade is an effective 
treatment option for MPM. The combination of nivolumab (anti-PD-1 antibody) 
and ipilimumab (anti-CTLA-4 antibody) could be a standard first-line treatment. 
Additionally, the combination of an ICI with conventional chemotherapy might 
be a promising treatment option. Cellular therapies and cancer vaccines must 
overcome many challenges, such as T-cell migration to the tumor and infiltration 
into the tumor. Improvements in cancer therapies are urgently needed to overcome 
these difficulties. Further research with large-scale clinical trials are needed to 
clarify the utility and safety of these immunotherapies in MPM. In addition, in this 
new era of precision medicine, we need to develop biomarkers to identify which 
patients would benefit from ICI-ICI combinations, ICI plus chemotherapy, or 
cellular therapy.
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